Aegera Therapeutics Inc., of Montreal, appointed James Rae chairman and Trudie Resch as a director.
Allos Therapeutics Inc., of Westminster, Colo., appointed Pablo Cagnoni senior vice president, chief medical officer.
Angiotech Pharmaceuticals Inc., of Vancouver, British Columbia, appointed Santi Corsaro vice president, sales and marketing.
Anthera Pharmaceuticals Inc., of San Mateo, Calif., appointed James Pennington executive vice president and chief medical officer.
Boston Life Sciences Inc., of Hopkinton, Mass., formed a science and technology committee comprised of independent directors. The committee is chaired by Robert Langer and includes Henry Brem and Gary Frashier.
Cerenis Therapeutics SA, of Toulouse, France, appointed H. Bryan Brewer, John Kastelein and Jean-Claude Tardif to its new scientific advisory board. Cerenis also appointed Mark Skaletsky as an independent director.
Chemokine Therapeutics Corp., of Vancouver, British Columbia, appointed C. Richard Piazza CEO. Hassan Salari, who held the position since he founded the company in 1998, will continue as president and now as chief scientific officer.
Codexis Inc., of Redwood City, Calif., appointed Michael Knauf vice president and general manager, bioindustrials.
DOR BioPharma Inc., of Miami, formed a North American medical advisory board to be chaired by George McDonald and including Joseph Antin, Joachim Deeg, Donna Przepiorka, Kirk Schultz, Keith Sullivan and Daniel Weisdorf.
Emergent BioSolutions Inc., of Rockville, Md., promoted Daniel Abdun-Nabi to president; Robert Kramer Sr. to executive vice president, manufacturing operations; Denise Esposito to senior vice president and general counsel; and Mauro Gibellini to senior vice president, corporate development.
Emisphere Technologies Inc., of Tarrytown, N.Y., formed a scientific advisory board chaired by Daniel Drucker and including Jay Skyler, Bernard Zinman Julio Rosenstock, Steven Kahn and Robert Gelfand.
Gene Logic Inc., of Gaithersburg, Md., elected Charles Dimmler III to serve as president and CEO. Mark Gessler will remain at the company and on the board.
Goodwin Procter LLP, of Boston, established an office in San Diego that will be led by Stephen Ferruolo and Ryan Murr.
Implicit Bioscience Pty. Ltd., of Brisbane, Australia, and Seattle, appointed Timothy Axtelle vice president, research and development.
Industrial Biotechnology Corp., of Sarasota, Fla., added Larry Drumm to its scientific advisory board.
Lexicon Genetics Inc., of The Woodlands, Texas, appointed Tamar Howson executive vice president of business development.
NanoLogix Inc., of Sharon, Pa., appointed Bret Barnhizer chairman, CEO and president. Former Chairman and CEO Mitchell Felder assumed the position of chief technology officer.
NeoStem Inc., of New York, said Richard Gatti joined its advisory board.
Paul Capital Partners, of New York, said John Leone joined the firm as a partner in its health care team.
Prana Biotechnology Ltd., of Melbourne, Australia, appointed Jeffrey Cummings chairman of its new research and development advisory board. The board also includes Jean-Marc Orgogozo, Steven Targum and Craig Ritchie, as well as Prana's co-founding scientists, Ashley Bush, Colin Masters and Rudolph Tanzi.